CorVel Corporation Q1 FY2027 earnings call

Leadership Transition

• The board completed a deliberate 18-month succession planning process, appointing Sarah Scott as the new President and CEO, with Michael Combs moving to the role of Executive Chairman.
• The board confirmed Scott has the deep business, customer, and cultural knowledge needed to lead Corvel into its next growth phase, with continuity supported by the existing executive leadership team.

Sales & Business Growth Metrics

• Quarterly year-over-year new customer sales improved over 60%, with nearly half of this growth achieved in June alone. Trailing 12-month new sales are up 40% compared to the prior 12-month period.
• RFP volume and average opportunity value both improved significantly compared to the year-ago quarter.

Strategic Product & Technology Initiatives

• The company continues to expand AI and automation across claims and clinical workflows, with deployed capabilities including claim summarization, risk identification, and clinical decision support. The tools augment professional judgment while maintaining full transparency, governance, and clinical oversight, and the company is standardizing impact measurement to guide future investment.
• A new Executive Advisory Services offering was launched to help clients evaluate workers' compensation and liability program performance, combining benchmarking, analytics, and operational expertise. The service is designed to add standalone value while deepening client relationships.
• A new data-driven medical bill repricing capability was launched to complement existing bill review and network solutions, supporting better reimbursement decisions and improved cost containment for out-of-network medical costs.
• In the group health market, the Cirrus segment continues expanding payment integrity capabilities and advancing new client implementations, with long-term opportunity to apply its commercial expertise to select government healthcare programs. Expansion will be evaluated based on market demand, return on investment, and program requirements.

Financial & Capital Management

• Corvel repurchased 377,098 shares in the quarter for $21.8 million. Since the start of the repurchase program, the company has repurchased 115.6 million shares for $910 million total, equal to 70% of original outstanding shares at an average price of $7.87 per share.
• Day sales outstanding improved to 39 days, a 1-day reduction year-over-year, indicating continued improvements in receivables management. Quarter-end cash balance was $256 million, and the company holds no debt, maintaining strong liquidity for future investment. Free cash flow for the quarter was $43.1 million, a $3.5 million year-over-year increase driven by lower net investing cash outflows.

For the June 2026 quarter, total company revenue was $260 million, representing an 11% year-over-year increase from $235 million in the June 2025 quarter. The two core business segments contributed equally to this total revenue growth:

1. Patient Management: Grew $12.5 million year-over-year, primarily driven by the enterprise claims TPA program. Claims volume across the business increased 8% year-over-year, the largest annual quarter-over-quarter growth since December 2024.
2. Network Solutions: Also grew $12.5 million year-over-year, with the Cirrus product segment acting as the top growth driver for this category.

On an overall basis, adjusted for one-time items, net income increased 18% year-over-year, with balanced performance across both segments. A one-time settlement of legacy accounts receivable in the Cirrus segment increased total earnings by approximately $0.07 per share for the quarter.

The management team did not provide explicit numerical forward-looking guidance or formal upward/downward revisions to prior growth projections in this earnings call. The company reaffirmed its long-term strategic priorities of disciplined execution, sustainable profitable growth, and fiscal responsibility, while noting it is well positioned to pursue new market opportunities thanks to its strong balance sheet and cash flow.

The call included an opening standard caution that forward-looking statements are projections, and actual results may differ materially from expectations due to unstated factors referenced in the company's SEC filings (including Form 10-K and Form 10-Q). No specific operational risks, financial risks, or ongoing operational failures were discussed explicitly during the call.

There were no questions submitted by meeting attendees during the Q&A portion of the webcast, so the call concluded early after the prepared remarks.